Explore more publications!

Vatican Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vatican Health Times.

Press releases published on November 25, 2025

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
2X Solutions Achieves SOC 2 Type II and HIPAA Compliance
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Septerna to Participate in 8th Annual Evercore Healthcare Conference
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
CytomX Therapeutics to Present at Upcoming December Investor Conferences
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
Compass Therapeutics to Participate in Upcoming December Investor Events
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
Historic Win for Electrophysiology Reimbursement in Ambulatory Surgery Centers Provides Unique Opportunity for Catheter Precision’s LockeT Device
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
PetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89%
Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions